US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.42 against a street estimate of 0.71 — a miss of 40.8%.
Analysts rate Amphastar P a buy (2 buy, 4 hold, 0 sell out of 6) with an average price target of $22.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.30% |
| Vanguard Group Inc | 5.92% |
| Dimensional Fund Advisors, Inc. | 4.60% |
| State Street Corp | 3.65% |
| Vanguard Capital Management, LLC | 3.50% |
| TD Asset Management Inc | 3.50% |
| Fuller & Thaler Asset Management Inc | 3.16% |
| Marshall Wace Asset Management Ltd | 2.33% |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Amphastar P — free to start.
Google PlayApp StoreData updated 2026-08-05.